Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer

Current Oncology

Volumn 14, Issue 4, 2007, Pages 149-153

  Hanna, Wedad ^a   O'Malley, Francis P ^b   Barnes, P ^c   Berendt, R ^c   Gaboury, L ^c   Magliocco, A ^c   Pettigrew, N ^c   Robertson, S ^c   Sengupta, S ^c   Tetu B ^c   Thomson, T ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c NONE

Author keywords

Breast cancer; Fluorescence in situ hybridization; HER2 neu; Immuno histochemistry; Quality assurance; Quality control; Testing guidelines

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ALGORITHM; ANTIGEN DETECTION; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANADA; CANCER GENETICS; CANCER INVASION; CANCER SCREENING; CLINICAL LABORATORY; CONSENSUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY AUTOMATION; MASTECTOMY; MEDICAL DOCUMENTATION; MEDICAL SOCIETY; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PREDICTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; VALIDATION STUDY;

EID: 49149104382     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.131     Document Type: Article

References (12)

1. Wolff A, Hammond M, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Yaziji H, Goldstein LC, Barry TS, et al. HER -2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291:1972-7.
4. Owens MA, Horten BC, Da Silva MM. HER 2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-9.
5. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232:1644-6.
6. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER 2 positive early breast cancer patients: BCIRG 006 study [abstract 1]. Breast Cancer Res Treat 2005;94(suppl 1):S5.
7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2-positive breast cancer. N Engl J Med 2005;353:1673-84.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353:1659-72.
10. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER 2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11.
11. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003;120:86-92.
12. Ellis IO, Bartlett J, Dowsett M, et al. Best Practice No 176: updated recommendations for HER 2 testing in the U.K. J Clin Pathol 2004;57:233-7.